Posts By :

Mea Holm, PhD

Mea Holm, PhD

The EAN President’s take on medical education

1024 625 Mea Holm, PhD

At the recent EAN 2018 congress, we met with Professor Franz Fazekas to discuss important advances and ongoing initiatives in medical education and continuous learning for neurologists. Prof. Fazekas is…

read more

Headaches and new ways to crush them

1800 1195 Mea Holm, PhD

At the ‘conference highlights’ session of the 2018 EAN meeting, Professor Isabel Pavão Martins presented a summary of the most groundbreaking research in the field of migraine. This highly burdensome…

read more

Rasagiline add-on treatment may offer hope to fast-progressing ALS patients

8001 4501 Mea Holm, PhD

At the ‘late breaking’ session of the EAN 2018 congress, Professor Albert Ludolph from Ulm University (Germany) unveiled the results of a recent double-blind, randomised Phase II trial of rasagiline…

read more

The many faces of progressive supranuclear palsy

1200 800 Mea Holm, PhD

Progressive supranuclear palsy (PSP)—a neurodegenerative disease characterized by tau pathology—can have a variety of clinical presentations, delegates heard at an EAN 2018 forum talk delivered by Prof. Günther Höglinger from…

read more

New app aims to facilitate cognitive screening of MS patients

3008 2008 Mea Holm, PhD

Dr. Stephen Rao from the Cleveland Clinic (Ohio, USA) presented a new tablet-based screening method for cognitive dysfunction at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting in Nashville,…

read more

FDA approves blockbuster migraine treatment

1200 800 Mea Holm, PhD

On May 17th, 2018, the US FDA approved Aimovig™ (erenumab) following successful phase III trials. Aimovig™, co-developed by Amgen and Novartis, is the first approved migraine treatment targeting the calcitonin gene…

read more
Brainwork is supported by unrestricted grants from: